Clinical settingPatients with metastatic cancer and unidentified primary tumour. All had been extensively tested with conventional diagnostic tests including labs tests, CT, X-ray and endoscopy (where appropriate).
Participants and Country45 patients. Germany
Study designRetrospective case series
Target conditionIdentification of the primary tumour site. Reference standard was
TestsFDG PET-CT Siemens Biograph. 350 MBq FDG. No attenuation correction. Comparator tests: PET, CT, PET-CT side by side
Follow upNot reported
Study TypeII
PET imaging fieldWhole body
Biopsy of metastasisAll had biopsy of at least one metastasis: adenocarcinoma 25/45 (56%), squamous cell carcinoma 15/45 (33%) and undifferentiated carcinoma 5/45 (11%).
NotesPossible overlap with Freundenberg 2005 series

From: Guideline chapter 2, Diagnosis

Cover of Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
NICE Clinical Guidelines, No. 104.
National Collaborating Centre for Cancer (UK).
Copyright © 2010, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.